Hiroaki Wakimoto

List of Publications by Year
in descending order

199 papers	16,815 citations	25034 57 h-index	18130 120 g-index
206 all docs	206 docs citations	206 times ranked	22181 citing authors

#	Article	IF	Citations
1	Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 2014, 344, 1396-1401.	12.6	3,648
2	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
3	Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell, 2014, 157, 580-594.	28.9	751
4	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science, 2017, 355, .	12.6	743
5	Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4822-4827.	7.1	425
6	Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science, 2015, 347, 273-277.	12.6	407
7	Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell, 2017, 20, 233-246.e7.	11.1	387
8	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology, 2019, 37, 1049-1058.	17.5	347
9	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell, 2015, 28, 773-784.	16.8	327
10	Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Medicine, 1999, 5, 881-887.	30.7	309
11	Human Glioblastomaâ€"Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. Cancer Research, 2009, 69, 3472-3481.	0.9	303
12	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4476-4481.	7.1	287
13	Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell, 2021, 39, 779-792.e11.	16.8	245
14	TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Molecular Cancer, 2010, 9, 194.	19.2	239
15	An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma. Cell Reports, 2013, 3, 1567-1579.	6.4	236
16	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
17	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
18	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro-Oncology, 2012, 14, 132-144.	1.2	185

#	Article	IF	Citations
19	Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12006-12011.	7.1	180
20	Usefulness of<scp>l</scp>-[methyl-¹¹C] methionineâ€"positron emission tomography as a biological monitoring tool in the treatment of glioma. Journal of Neurosurgery, 2005, 103, 498-507.	1.6	167
21	Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell, 2017, 32, 411-426.e11.	16.8	161
22	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i>-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
23	Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. , 1996, 77, 373-380.		141
24	Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant. Journal of Virology, 2000, 74, 4765-4775.	3.4	133
25	Gene therapy for ?-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology, 1996, 23, 1359-1368.	7.3	128
26	Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. Journal of Neurosurgery, 2010, 113, 310-318.	1.6	113
27	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clinical Cancer Research, 2016, 22, 4452-4465.	7.0	112
28	Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Therapy, 2003, 10, 983-990.	4.5	111
29	Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Therapy, 2004, 11, 214-223.	4.5	108
30	IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nature Cell Biology, 2019, 21, 1003-1014.	10.3	107
31	Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Therapy, 2006, 13, 705-714.	4.5	104
32	Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells. Journal of the National Cancer Institute, 2012, 104, 42-55.	6.3	103
33	Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy. Journal of the National Cancer Institute, 2014, 106, dju090.	6.3	102
34	Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy. Molecular Therapy, 2015, 23, 108-118.	8.2	97
35	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cellâ€"Delivered TRAIL in Experimental Glioma Models. Cancer Research, 2011, 71, 154-163.	0.9	94
36	Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9085-9089.	7.1	92

#	Article	IF	Citations
37	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6157-E6165.	7.1	90
38	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	1.8	89
39	Effect of Î³34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain Tumors. Journal of Virology, 2012, 86, 4420-4431.	3.4	85
40	The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(â€”). Cancer Research, 2016, 76, 2954-2963.	0.9	84
41	Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. Journal of Neurosurgery, 2013, 119, 1145-1155.	1.6	78
42	The Complement Response Against an Oncolytic Virus Is Species-Specific in Its Activation Pathways. Molecular Therapy, 2002, 5, 275-282.	8.2	77
43	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature Communications, 2019, 10, 2910.	12.8	77
44	Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. Clinical Cancer Research, 2020, 26, 1690-1699.	7.0	76
45	YB-1 Bridges Neural Stem Cells and Brain Tumorâ€"Initiating Cells via Its Roles in Differentiation and Cell Growth. Cancer Research, 2011, 71, 5569-5578.	0.9	74
46	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD+ Depletionâ€"Mediated Cytotoxicity. Cancer Research, 2017, 77, 4102-4115.	0.9	74
47	Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts. Clinical Cancer Research, 2011, 17, 7383-7393.	7.0	73
48	A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells. Clinical Cancer Research, 2011, 17, 3686-3696.	7.0	73
49	Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16642-16647.	7.1	70
50	Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro-Oncology, 2019, 21, 1401-1411.	1.2	70
51	Immunohistochemical Detection of Progesterone Receptors and the Correlation with Ki-67 Labeling Indices in Paraffin-embedded Sections of Meningiomas. Neurosurgery, 1995, 37, 478-483.	1.1	68
52	Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells, 2012, 30, 1064-1075.	3.2	66
53	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	7.7	66
54	Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. Gastroenterology, 1996, 111, 1241-1251.	1.3	65

#	Article	IF	Citations
55	Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models. Neoplasia, 2013, 15, 591-599.	5.3	65
56	The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. Molecular Therapy, 2015, 23, 1234-1247.	8.2	62
57	Malignant transformation eight years after removal of a benign epidermoid cyst: a caseâ€report. Journal of Neuro-Oncology, 2006, 79, 67-72.	2.9	61
58	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathologica Communications, 2020, 8, 171.	5.2	58
59	DECREASE IN ELASTIN GENE EXPRESSION AND PROTEIN SYNTHESIS IN FIBROBLASTS DERIVED FROM CARDINAL LIGAMENTS OF PATIENTS WITH PROLAPSUS UTERI. Cell Biology International, 1997, 21, 605-611.	3.0	57
60	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in <i>PIK3CA</i>-Mutant Breast Cancer Brain Metastases. Clinical Cancer Research, 2019, 25, 3374-3383.	7.0	57
61	Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma . Oncolytic Virotherapy, 2019, Volume 8, 27-37.	6.0	54
62	Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?. Future Oncology, 2010, 6, 619-634.	2.4	52
63	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenaseâ€"mutant Glioma. Clinical Cancer Research, 2019, 25, 1261-1271.	7.0	50
64	PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Research, 2003, 63, 2300-5.	0.9	50
65	Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction. Journal of Cancer Research and Clinical Oncology, 1995, 121, 587-592.	2.5	49
66	Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors. Molecular Therapy, 2013, 21, 68-77.	8.2	46
67	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 3318-3328.	7.0	45
68	Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Frontiers in Microbiology, 2014, 5, 303.	3.5	44
69	Oncolytic herpes simplex virus interactions with the host immune system. Current Opinion in Virology, 2016, 21, 26-34.	5.4	44
70	Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clinical Cancer Research, 2018, 24, 3409-3422.	7.0	44
71	Directed evolution of adeno-associated virus for glioma cell transduction. Journal of Neuro-Oncology, 2010, 96, 337-347.	2.9	43
72	Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling. Cancers, 2019, 11, 1651.	3.7	43

#	Article	IF	Citations
73	Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Therapy, 2002, 9, 228-235.	4.6	42
74	Emerging Medical Treatments for Meningioma in the Molecular Era. Biomedicines, 2018, 6, 86.	3.2	42
75	Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells, 2021, 39, 707-722.	3.2	42
76	Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clinical Cancer Research, 2021, 27, 889-902.	7.0	41
77	Genotype-targeted local therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8388-E8394.	7.1	40
78	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology, 2018, 20, 642-654.	1.2	39
79	CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Science Translational Medicine, 2018, 10, .	12.4	39
80	Expression of FMS-like Tyrosine Kinase 3 Ligand by Oncolytic Herpes Simplex Virus Type I Prolongs Survival in Mice Bearing Established Syngeneic Intracranial Malignant Glioma. Neurosurgery, 2012, 71, 741-748.	1.1	35
81	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro-Oncology, 2017, 19, now253.	1.2	35
82	Rad51 Degradation: Role in Oncolytic Virusâ€"Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Journal of the National Cancer Institute, 2017, 109, 1-13.	6.3	35
83	Clinical and prognostic features of spinal meningioma: a thorough analysis from a single neurosurgical center. Journal of Neuro-Oncology, 2018, 140, 639-647.	2.9	35
84	Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188458.	7.4	34
85	Oncolytic Herpes Simplex Virus Counteracts the Hypoxia-Induced Modulation of Glioblastoma Stem-Like Cells. Stem Cells Translational Medicine, 2012, 1, 322-332.	3.3	33
86	Blockade of transforming growth factorâ€Î² signaling enhances oncolytic herpes simplex virus efficacy in patientâ€derived recurrent glioblastoma models. International Journal of Cancer, 2017, 141, 2348-2358.	5.1	33
87	Modulation of Motility and Proliferation of Glioma Cells by Hepatocyte Growth Factor. Japanese Journal of Cancer Research, 1997, 88, 564-577.	1.7	32
88	Herpes Simplex Virus Us3(â^') Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Aktâ€"Targeting Molecular Therapeutics. Clinical Cancer Research, 2007, 13, 5897-5902.	7.0	32
89	Targeting Hypoxia-Inducible Factor 1Î± in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. Journal of Neuropathology and Experimental Neurology, 2015, 74, 710-722.	1.7	32
90	microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro-Oncology, 2018, 20, 215-224.	1.2	32

#	Article	IF	Citations
91	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathologica, 2020, 140, 89-93.	7.7	32
92	P53 Overexpression and Proliferative Potential in Malignant Meningiomas. Acta Neurochirurgica, 1999, 141, 53-61.	1.7	30
93	Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. Journal of Neuro-Oncology, 2015, 121, 91-100.	2.9	30
94	Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discovery, 2020, 10, 1672-1689.	9.4	30
95	The Combination of Adenoviral HSV TK Gene Therapy and Radiation is Effective in Athymic Mouse Glioblastoma Xenografts without Increasing Toxic Side Effects. Journal of Neuro-Oncology, 2004, 67, 177-188.	2.9	29
96	MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma. Neuro-Oncology, 2021, 23, 2014-2027.	1.2	29
97	Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication. Cancer Research, 2010, 70, 3890-3895.	0.9	28
98	PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiencyâ€"Mediated Acquired Resistance to Temozolomide. Molecular Cancer Therapeutics, 2018, 17, 2551-2563.	4.1	28
99	Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma. Cancer Research, 2020, 80, 5024-5034.	0.9	28
100	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas. Neurosurgery, 2017, 64, 134-138.	1.1	27
101	Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. International Journal of Cancer, 2017, 141, 1671-1681.	5.1	26
102	Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of Î³34.5 in Glioblastoma Stem-Like Cells. Journal of Virology, 2018, 92, .	3.4	26
103	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
104	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. OncoImmunology, 2020, 9, 1806662.	4.6	26
105	Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications, 2020, 8, 221.	5.2	26
106	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro-Oncology, 2016, 18, 1278-1287.	1.2	25
107	Efficient Retrovirus-mediated Cytokine-gene Transduction of Primary-cultured Human Glioma Cells for Tumor Vaccination Therapy. Japanese Journal of Cancer Research, 1997, 88, 296-305.	1.7	24
108	At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology. Cancer Research, 2016, 76, 994-998.	0.9	24

#	Article	IF	Citations
109	Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells, 2021, 10, 1541.	4.1	24
110	Immunohistochemical Detection of Ki-67 in Replicative Smooth Muscle Cells of Rabbit Carotid Arteries After Balloon Denudation. Stroke, 1995, 26, 2328-2332.	2.0	24
111	Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma. JCO Precision Oncology, 2020, 4, 593-613.	3.0	21
112	Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Molecular Therapy - Oncolytics, 2019, 13, 58-66.	4.4	20
113	Bidirectional Regulation between NDRG1 and GSK3Î² Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma. Cancer Research, 2020, 80, 234-248.	0.9	20
114	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Research, 2020, 80, 5330-5343.	0.9	19
115	Topography of transcriptionally active chromatin in glioblastoma. Science Advances, 2021, 7, .	10.3	19
116	Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application. Expert Opinion on Biological Therapy, 2019, 19, 845-854.	3.1	17
117	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <i>BRAFV600E</i>-mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	7.0	17
118	Enhancement of retrovirus-mediated gene transduction efficiency by transient overexpression of the amphotropic receptor, GLVR-2. Nucleic Acids Research, 1995, 23, 2080-2081.	14.5	16
119	In VivoAntitumor Effect of Cytotoxic T Lymphocytes Engineered to Produce Interferon-Î³ by Adenovirus-Mediated Genetic Transduction. Biochemical and Biophysical Research Communications, 1996, 218, 164-170.	2.1	16
120	Impairment of Both Apoptotic and Cytoprotective Signalings in Glioma Cells Resistant to the Combined Use of Cisplatin and Tumor Necrosis Factor Î±. Clinical Cancer Research, 2004, 10, 234-243.	7.0	16
121	Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62.	1.2	15
122	Interferon-Î³ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Developmental Cell, 2022, 57, 1847-1865.e9.	7.0	15
123	Recurrence in meningeal hemangiopericytomas. World Neurosurgery, 1998, 50, 586-591.	1.3	14
124	Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma. Viruses, 2014, 6, 3080-3096.	3.3	13
125	Augmented Antitumor Effects of Killer Cells Induced by Tumor Necrosis Factor Gene-Transduced Autologous Tumor Cells from Gastrointestinal Cancer Patients. Human Gene Therapy, 1996, 7, 1895-1905.	2.7	12
126	In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells. Gene Therapy, 2015, 22, 947-959.	4.5	12

#	Article	IF	Citations
127	EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, AÂSMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2. Neuro-Oncology, 2017, 19, vi81-vi81.	1.2	12
128	A Monoclonal Antibody Against Î²1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Targeted Oncology, 2019, 14, 479-489.	3.6	12
129	Development of a novel non-human primate model for preclinical gene vector safety studies. Determining the effects of intracerebral HSV-1 inoculation in the common marmoset: a comparative study. Gene Therapy, 2003, 10, 1225-1233.	4.5	11
130	Long-term outcomes of multimodality management for parasagittal meningiomas. Journal of Neuro-Oncology, 2020, 147, 441-450.	2.9	11
131	Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432. Cancer Immunology, Immunotherapy, 1995, 41, 82-86.	4.2	10
132	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight, 2021, 6, .	5.0	10
133	Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. Neurosurgical Focus, 2022, 52, E6.	2.3	10
134	Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature Communications, 2022, 13, 2810.	12.8	10
135	Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas. Clinical Neurology and Neurosurgery, 2001, 103, 13-18.	1.4	9
136	Immunovirotherapy for glioblastoma. Cell Cycle, 2014, 13, 175-176.	2.6	9
137	Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports, 2019, 9, 139.	3.3	9
138	Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends in Cancer, 2020, 6, 147-159.	7.4	9
139	Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. Journal of Experimental Therapeutics and Oncology, 2002, 2, 100-106.	0.5	7
140	Glioblastoma: State of the Art and Future Perspectives. Cancers, 2019, 11, 1091.	3.7	7
141	Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. American Journal of Cancer Research, 2016, 6, 300-11.	1.4	7
142	Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest. Methods in Molecular Biology, 2019, 1937, 177-188.	0.9	6
143	Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma. Frontiers in Oncology, 2020, 10, 568079.	2.8	6
144	Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches. American Journal of Cancer Research, 2021, 11, 3742-3754.	1.4	6

#	Article	IF	Citations
145	Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice. Brain Research, 2022, 1774, 147706.	2.2	5
146	Correlation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery. Cancers, 2022, 14, 1449.	3.7	5
147	Abstract 1122: ATR inhibitors synergize with PARP inhibitors in killing glioblastoma stem cells and treating glioblastoma. , 2017, , .		3
148	ATPS-852-HYDROXYGLUTARATE DEPLETION IS NOT SUFFICIENT TO INHIBIT GROWTH OF SEVERAL PROGRESSIVE IDH1 MUTANT SOLID CANCER TYPES. Neuro-Oncology, 2015, 17, v37.2-v37.	1.2	2
149	High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma. Frontiers in Oncology, 2020, 10, 542294.	2.8	2
150	Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. , 2016, , .		2
151	<i>TERT</i> promoter mutations in progressive treatment-resistant meningiomas.. Journal of Clinical Oncology, 2017, 35, 2047-2047.	1.6	2
152	Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype. Journal of Neuro-Oncology, 2023, 161, 193-202.	2.9	2
153	CSIG-29. THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND IN VIVO. Neuro-Oncology, 2018, 20, vi49-vi49.	1.2	1
154	Abstract 4004: Molecular characterization of circulating glioblastoma cells identifies a mesenchymal-like tumor cell subpopulation. , 2014, , .		1
155	Deubiquitinating ALDH1A3 key to maintaining the culprit of aggressive brain cancer. Journal of Clinical Investigation, 2019, 129, 1833-1835.	8.2	1
156	ET-17 * TRANSIENT FASTING ENHANCES REPLICATION AND THERAPEUTIC ACTIVITY OF ONCOLYTIC HSV IN GLIOBLASTOMA THERAPY. Neuro-Oncology, 2014, 16, v82-v83.	1.2	0
157	107. Tracking Target Cell Fate After Oncolytic Herpes Simplex Virus Infection. Molecular Therapy, 2016, 24, S46.	8.2	0
158	CSIG-33. BETA 1 INTEGRIN INHIBITION IN HIGH-GRADE MENINGIOMA. Neuro-Oncology, 2017, 19, vi56-vi56.	1.2	0
159	151 TERT Promoter Mutations in Progressive Treatment-resistant Meningiomas. Neurosurgery, 2017, 64, 236-237.	1.1	0
160	DRES-16. PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOMA MODELS. Neuro-Oncology, 2017, 19, vi67-vi67.	1.2	0
161	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD+ DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. Neuro-Oncology, 2017, 19, vi75-vi75.	1.2	0
162	EXTH-60. PLK1 INHIBITOR TARGETS MISMATCH REPAIR DEFICIENT TEMOZOLOMIDE RESISTANT GLIOMA. Neuro-Oncology, 2017, 19, vi86-vi86.	1.2	0

#	Article	IF	Citations
163	CBIO-12. GTP METABOLIC SWITCH LEADS TO NUCLEOLAR TRANSFORMATION AND MALIGNANT GROWTH OF GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi35-vi35.	1.2	0
164	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. Neuro-Oncology, 2018, 20, vi157-vi157.	1.2	0
165	EXTH-20. HISTONE DEACETYLASE INHIBITOR ENHANCES ONCOLYTIC HERPES SIMPLEX VIRUS THERAPY FOR MALIGNANT MENINGIOMA. Neuro-Oncology, 2018, 20, vi89-vi89.	1.2	0
166	CSIG-34. PI3 KINASE PATHWAY ACTIVATION PROMOTES MALIGNANT PROGRESSION IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology, 2018, 20, vi50-vi50.	1.2	0
167	Bispecific T-Cell Engager -Armored Chimeric Antigen Receptor T Cells Overcome Antigen Escape From EGFRvIII-Targeted Therapy For Glioblastoma. Neurosurgery, 2019, 66, 310-154.	1.1	0
168	CBMT-47. MODULATION OF NAD PATHWAYS AS A THERAPEUTIC STRATEGY FOR TARGETING IDH MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi43-vi43.	1.2	0
169	DRES-05. PREDICTORS OF SENSITIVITY TO COMBINED TEMOZOLOMIDE AND PARP INHIBITOR IN GLIOMA. Neuro-Oncology, 2019, 21, vi72-vi72.	1.2	0
170	SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS. Neuro-Oncology Advances, 2019, 1, ii7-ii7.	0.7	0
171	TB-02 NF-KB CANONICAL PATHWAY ACTIVATION DRIVES GLYCOLYSIS AND TUMOR PROGRESSION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology Advances, 2019, 1, ii10-ii10.	0.7	0
172	EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION. Neuro-Oncology, 2019, 21, vi93-vi93.	1.2	0
173	TMIC-25. MODIFICATION OF EXTRACELLULAR MATRIX ENHANCES ONCOLYTIC ADENOVIRUS IMMUNOTHERAPY IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi252-vi253.	1.2	0
174	DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS. Neuro-Oncology Advances, 2021, 3, i6-i7.	0.7	0
175	OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma. Neuro-Oncology Advances, 2021, 3, ii9-ii9.	0.7	0
176	Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities. , 2021, , .		0
177	OTME-7. Cancer - immune cell interactions drive transitions to mesenchymal-like state in glioblastoma. Neuro-Oncology Advances, 2021, 3, ii14-ii15.	0.7	0
178	Abstract C176: Combining oncolytic herpes simplex virus and chemotherapy: G47 and temozolomide synergize in killing glioma stem cells. , 2009, , .		0
179	Abstract LB-101: Y-box binding protein-1 (YB-1) inhibition triggers differentiation of normal and cancer stem cells from the brain. , 2011, , .		0
180	Abstract 5389: Oncolytic herpes simplex virus expressing interleukin-12 for treating glioma stem cells. , 2011, , .		0

#	Article	IF	Citations
181	Glioblastoma-Derived Cancer Stem Cells: Treatment with Oncolytic Viruses. , 2012, , 121-128.		0
182	Adoptive Immunotherapy with Cytokine Gene-modified Cytotoxic T Lymphocytes. , 1996, , 174-189.		0
183	Targetable signaling pathway mutations and progression of <i>IDH</i>-mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
184	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
185	Abstract 4227: PARP inhibitors sensitize glioblastoma stem cells to oncolytic herpes simplex virus therapy. , 2015, , .		0
186	Abstract LB-301: PLK1 inhibitor targets mismatch repair-deficient temozolomide-resistant tumors. , 2017, , .		0
187	Abstract LB-334: xCT promotes malignant phenotypes in EGFR-expressing glioma. , 2017, , .		0
188	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. Neuro-Oncology, 2021, 23, vi123-vi123.	1.2	0
189	EXTH-54. PHOTODYNAMIC ONCOLYTIC VIROTHERAPY INCORPORATING GENETICALLY ENGINEERED PHOTOSENSITIZER KILLERRED FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM MALIGNANCIES. Neuro-Oncology, 2021, 23, vi175-vi175.	1.2	0
190	TAMI-12. CANCER-IMMUNE CELL INTERACTIONS DRIVE TRANSITIONS TO MESENCHYMAL-LIKE STATES IN GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi200-vi200.	1.2	0
191	EXTH-73. PROTEASOME INHIBITION EXPOSES SELECTIVE VULNERABILITY IN CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology, 2021, 23, vi180-vi180.	1.2	0
192	Interferon-Î³ Resistance and Immune Evasion in Glioma Develop via Notch-Regulated Co-Evolution of Malignant and Immune Cells. SSRN Electronic Journal, 0, , .	0.4	0
193	Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology, 2020, 22, 1894-1894.	1.2	0
194	TAMI-30. LOCAL TARGETING OF NAD+ SALVAGE PATHWAY ALTERS THE IMMUNE TUMOR MICROENVIRONMENT AND ENHANCES CHECKPOINT IMMUNOTHERAPY IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii219-ii219.	1.2	0
195	CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma. Neuro-Oncology Advances, 2020, 2, ii4-ii4.	0.7	0
196	EXTH-10. COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS. Neuro-Oncology, 2020, 22, ii88-ii89.	1.2	0
197	TAMI-36. CONNEXIN 43 BLOCKADE INHIBITS PROLIFERATION IN IDH1-MUTANT GLIOMA CELLS. Neuro-Oncology, 2020, 22, ii220-ii221.	1.2	0
198	TAMI-20. POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITION SEQUESTERS NAD+ TO POTENTIATE THE METABOLIC LETHALITY OF ALKYLATING CHEMOTHERAPY IN IDH MUTANT TUMOR CELLS. Neuro-Oncology, 2020, 22, ii217-ii217.	1.2	0

#	Article	IF	Citations
199	Abstract 1841: MRTX849 inhibits P-gp and demonstrates CNS exposure in mouse models and cancer patients and demonstrates antitumor activity in intracranial mouse models of lung cancer brain metastasis. Cancer Research, 2022, 82, 1841-1841.	0.9	0